Browsing by Author "Şahbazlar M."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
    (Springer, 2024) Beypınar İ.; Demir H.; Yaslıkaya Ş.; Köşeci T.; Demir B.; Çolak G.; Ağaoğlu A.B.; Şahbazlar M.; Şancı P.C.; Çabuk D.; Işık U.; Şahin E.; Coşkun A.; Caner B.; Aykut T.; Artaç M.; Duygulu M.E.; Sever N.; Öksüz S.; Turan N.; Aykan M.B.; Tüzün E.K.; Uysal M.; Uğurlu İ.; Sakin A.; Acar C.; Özaşkın D.; Şakalar T.; Keskinkılıç M.; Yavuzşen T.; Köse N.; Ertürk İ.; Yıldırım N.; Balçık O.Y.; Alkan A.; Selvi O.; Erçin E.; Ünal O.Ü.; Karaçin C.
    Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
  • No Thumbnail Available
    Item
    The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
    (Nature Research, 2024) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aydın E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1–0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied. © The Author(s) 2024.
  • No Thumbnail Available
    Item
    Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Sever N.; Şimşek F.; Onur İ.D.; Arvas H.; Guliyev T.; Şakalar T.; Çiçek C.M.; Orman S.; Çetin E.B.; Kayaş K.; Akbaş S.; Ağyol Y.; Güren A.K.; Erel P.; Kocaaslan E.; Paçacı B.; Tunç M.A.; Çelebi A.; Majidova N.; Durnalı A.; Şimşek M.; Şahbazlar M.; Işık S.; Arıkan R.; Ercelep Ö.; Sarı M.; Köstek O.; Bayoğu İ.V.
    Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients received either double (cisplatin + doxorubicin) or triple (MAP or PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models. Results: The median age was 20 years (IQR: 18–29), and 53.1% were male. Patients who received triple chemotherapy regimens demonstrated significantly longer overall survival (OS) compared to those on doublet regimens. High tumor necrosis rates (>90%) and negative surgical margins were strongly associated with improved OS, while metastatic disease at diagnosis, elevated alkaline phosphatase (ALP), and male gender were linked to poorer survival. Multivariate analysis identified adjuvant therapy, age under 18, high necrosis rate, negative margins, and normal ALP as significant OS predictors. Conclusions: Triple-agent chemotherapy, necrosis rate ≥90 and negative surgical margins are strongly associated with prolonged survival in osteosarcoma. The key prognostic indicators such as ALP levels, surgical margins and age at diagnosis should guide personalized treatment strategies to improve outcomes in curable patients. © 2025 by the authors.
  • No Thumbnail Available
    Item
    Correction to: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (Scientific Reports, (2024), 14, 1, (23556), 10.1038/s41598-024-75293-5)
    (Nature Research, 2025) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aşık E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Aydın E.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
    Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-75293-5, published online 09 October 2024 The original version of this Article contained an error in the spelling of the author Esra Aşık which was incorrectly given as Esra Aydın. The original Article has been corrected. © The Author(s) 2024.